Optimizing management of musculoskeletal pain disorders in primary physiotherapy care

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
05/01/2021		∐ Protocol		
Registration date	Overall study status Completed	[X] Statistical analysis plan		
18/01/2021		Results		
Last Edited	Condition category Musculoskeletal Diseases	Individual participant data		
04/12/2024		[X] Record updated in last year		

Plain English summary of protocol

Background and study aims

Musculoskeletal disorders (MSDs) are the number one cause of years lived with disability and reduced health worldwide. In Norway, every fourth patient in primary care suffers from MSDs. Treatment effects are however modest and knowledge of best practice limited. The SupportPrim project will address these challenges in two main steps:

Firstly, to optimize person-centered care, we will employ methods from artificial intelligence in terms of Case-Based Reasoning to build a clinical decision support system (cDSS) based on patient data already collected in primary care physiotherapy. Case-Based Reasoning aims to solve new problems based on the solutions to similar problems in the past. In other words, previous MSD cases will be used to help similar cases in the future, just as humans learn from their own experience. We will then assess the efficacy of the cDSS in physiotherapy practice in a cluster-randomized controlled trial.

Secondly, this effort will be expanded to general practice by implementing The STarT MSK screening Tool as the basis for stratified care for MSD patients. The efficacy of stratified care will be assessed in a cluster-randomized controlled trial in general practice.

Who can participate?

Adults over 18 years, presenting to a primary care physiotherapist with musculoskeletal pain disorder in any of these areas; shoulder, neck, upper/low back, hip, knee or with multisite pain as primary contact reason. Also 40 physiotherapists will participate.

What does the study involve?

The physiotherapists will be randomly allocated to receive access to the cDSS to aid their physiotherapy practice or to continue giving treatment as usual. Patients will be treated by the physiotherapists and data will be regularly collected for 12 months to assess if the cDSS is contributing to improved outcomes for patients.

What are the possible benefits and risks of participating?

Benefits for those in the intervention group is access to a comprehensive overview of the patient's characteristics and reported symptoms at initiation of treatment, as well as treatment advice (on-screen) based on previous, similar patients with successful outcome, which is to be used in a co-decision process between therapist and patient for optimal management of the

current patient.

Participation in the project does not entail any risks or disadvantages in relation to ordinary physiotherapy treatment, as management is at the discretion of the therapist.

Where is the study run from?

Norwegian University of Science and Technology in collaboration with 40 physiotherapists at different private primary care clinics throughout Norway

When is the study starting and how long is it expected to run for? February 2019 to September 2022

Who is funding the study?
Norges Forskningsråd (Norwegian Research Council)

Who is the main contact?
Dr Ingebrigt Meisingset, Ingebrigt.meisingset@ntnu.no

Contact information

Type(s)

Scientific

Contact name

Dr Ingebrigt Meisingset

Contact details

Department of Public Health and Nursing Faculty of Medicine and Health Science Norwegian University of Technology and Science Trondheim Norway N-7491

• •

Ingebrigt.meisingset@ntnu.no

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Project number NRC: 303331

Study information

Scientific Title

An AI-based clinical decision support system for personalized care of common musculoskeletal pain disorders in primary physiotherapy care

Acronym

SupportPrim

Study objectives

Relative to usual care, we hypothesize that personalized care provided by a clinical decision support system founded in artificial intelligence results in better globally perceived effects and improved function among patients with common musculoskeletal disorders in primary physiotherapy care.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 08/09/2020, Regional Committee for Medical Research Ethics - Mid Norway (NTNU /REK midt, Det medisinske fakultet, Postboks 8905, 7491 Trondheim, Norway; +47 73 59 75 11; rek-midt@mh.ntnu.no), ref. 493080

Study design

Multicentre cluster-randomized controlled trial where individual physiotherapists serve as clusters

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Improved treatment outcome for patients with common musculoskeletal disorders such as neck, shoulder, low back, hip, knee and multisite pain

Interventions

To implement personalized care, we will employ innovative methods from artificial intelligence (AI) in terms of Case-Based Reasoning (CBR) to build a clinical decision support system (cDSS) based on patient data already collected in primary care physiotherapy. The CBR methodology will be used to match new patients to previous, similar patients with successful outcome, i.e. it enables a patient-centered intervention based on what has been successful in previous, similar cases. Results from the CBR will be displayed in a clinical dashboard, i.e. the cDSS, for shared decision-making and optimal management of new patients with common musculoskeletal disorders.

Physiotherapists in the intervention group will be provided access to the cDSS, while physiotherapist randomized to the usual care group will carry on patient management as usual without access to the cDSS.

Duration of treatment and number of treatments is at the discretion of each therapist and it is up to each therapist to terminate the treatment. Patients are followed up for 12 months for the purposes of data collection.

Randomisation

We will randomise the therapists (clusters) in 1:1 ratio to the control and intervention groups (automated computerized procedure).

Intervention Type

Other

Primary outcome(s)

- 1. Patients' assessment of their condition measured by Global perceived effect (GPE), a seven-point Likert scale, at 3, 6 and 12 months. The GPE scale will be dichotomized as "improved" (score 1-2) or "unchanged/worse" (score 3-7).
- 2. Clinically important improvement in function, measured by the Patient Specific Function Scale (PSFS; 0-10), where a 30% change is defined as a Minimal clinically important difference (MCID). PSFS will be measured at baseline, 2, 4, 8 and 12 weeks

Key secondary outcome(s))

At baseline and 3, 6 and 12 month follow-up secondary outcomes include:

- 1. Pain intensity (NRS; 0-10)
- 2. Pain drawing, number of pain sites
- 3. Pain mapping; how often, continuous (of and on), daily variation
- 4. EQ-5D-5L (quality of life), five items
- 5. 15D (health-related quality of life, two items; sleep and vitality
- 6. Musculoskeletal Health Questionnaire (MSK-HQ)
- 7. Number of treatments by 3 months (patient records)
- 8. Patient-specific functional scale (PSFS; 0-10)
- 9. Work ability (single item from Work Ability Index; current work ability compared with life-time best
- 10. Work status/sick leave (patient records)
- 11. Medication (patient records)
- 12. Patient-therapist relationship (3 questions); overall satisfaction, belief in therapist's competency, and communication
- 13. Benefits of physiotherapy and expectations to physiotherapist (2 questions)
- 14. Adherence to treatment plan (5 alternatives)
- 15. Goal achievement (not, partly, or fully achieved) (patient records)
- 16. Most important reason for success/non-success (text), at 3 months only
- 17. Still receiving physiotherapy after 3, 6 and 12 months (yes/no)
- 18. Physical activity, 3 questions; frequency, intensity and duration
- 19. Hopkins Symptom Check List, HSCL-10 (emotional distress)
- 20. Pain Self efficacy, 2 questions (from PSEQ 2-item)
- 21. Cost-utility based on patients deductibles and costs covered by the Norwegian Health Economics Administration (HELFO) and utility measured by EQ-5D

At 2, 4 and 8 weeks secondary outcomes collected by SMS (text-messages):

- 1. Patient-specific functional scale
- 2. Work ability

- 3. Global perceived effect score
- 4. Pain intensity, at 2 and 8 weeks only
- 5. Pain self-efficacy, at 2 and 8 weeks only

Completion date

01/09/2022

Eligibility

Key inclusion criteria

- 1. Patients presenting to a primary care physiotherapist with musculoskeletal pain disorder in any of these areas; shoulder, neck, upper/low back, hip, knee or with multisite pain as primary contact reason.
- 2. Age above 18 years
- 3. Physiotherapists with the patient participants in their current patient population

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Αll

Total final enrolment

298

Key exclusion criteria

- 1. Reduced cognitive function or skills in Norwegian (impeding reading, speaking or comprehension of Norwegian language)
- 2. Neurological diagnosis (e.g. multiple sclerosis, stroke, ALS, Parkinson, dementia)
- 3. On-going cancer
- 4. Pregnancy or pregnancy-related disorders
- 5. Scheduled for surgery or recent surgery or fracture within the last 6 months

Date of first enrolment

01/02/2021

Date of final enrolment

30/11/2021

Locations

Countries of recruitment

Norway

Study participating centre

Norwegian University of Science and Technology in collaboration with 40 physiotherapists at different private primary care clinics throughout Norway

Faculty of Medicine and Health Sciences Department of Public Health and Nursing P.O.Box 8905 Trondheim Norway N-7491

Sponsor information

Organisation

Norwegian University of Science and Technology

ROR

https://ror.org/05xg72x27

Funder(s)

Funder type

Government

Funder Name

Norges Forskningsråd

Alternative Name(s)

Forskningsrådet, Norwegian Research Council, Research Council of Norway, The Research Council of Norway

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Norway

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. Dr Ingebrigt Meisingset, Ingebrigt. meisingset@ntnu.no. Anonymized clustered and participant-level data can be shared after acceptance of publications of main results, providing a relevant research question and ethical approval of the study protocol is documented, including whether data sharing is covered by the current, approved consent from participants. Collaborative research efforts and work is appreciated.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			04/02/2021	No	Yes
Participant information sheet			04/02/2021	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Statistical Analysis Plan	version 1.0	14/06/2022	01/07/2022	No	No
Statistical Analysis Plan	version 2.0	01/03/2023	01/03/2023	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes